A Phase 2 randomized, double-blind, placebo-controlled study of ATA188 for Progressive Forms of Multiple Sclerosis
Latest Information Update: 18 Jan 2022
At a glance
- Drugs ATA 188 Allogeneic (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2022 According to an Imeka media release, the company collaborates with Atara Biotherapeutics to utilize Imeka's novel biomarker technology in this study.
- 04 May 2021 According to an Atara Biotherapeutics media release, filed and received approval of a Clinical Trial Application (CTA) for the Phase 2 RCT in Canada
- 13 Jan 2021 New trial record